Idorsia Ltd
🇨🇭Switzerland
To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04281342
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT04255277
- Locations
- 🇫🇷
Site 1, Rennes, France
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT04252495
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇵🇱Biokinetica S.A., Jozefow, Poland
A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04250506
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT04183686
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Registration Number
- NCT04162366
A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04123288
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04052360
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04024332
- Locations
- 🇩🇪
APEX GmbH, München, Germany
A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03913000
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
© Copyright 2024. All Rights Reserved by MedPath